Blog

What it Treats PHESGO ™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PHESGO should be used as part…

Andreia Gameiro 1, Ana Catarina Urbano 1, Fernando Ferreira 1 Affiliations expand PMID: 34437486 PMCID: PMC8402877 DOI: 10.3390/vetsci8080164 Free PMC article Abstract Feline mammary carcinoma (FMC) is a common aggressive malignancy with a low survival rate that lacks viable therapeutic options beyond mastectomy. Recently, increasing efforts have been made to understand the molecular mechanisms underlying FMC development, using the knowledge gained from studies on…

Sandrine Richard 1, Frédéric Selle 1, Jean-Pierre Lotz 1 2, Ahmed Khalil 1, Joseph Gligorov 1 2, Daniele G Soares 1 Affiliations expand PMID: 27275646 DOI: 10.1590/0001-3765201620150178 Free article Abstract It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease,…

By Josh Sullivan The fast-growing mRNA biotech Moderna has struck a deal to build a new manufacturing facility in Canada that will provide a full supply of their vaccines to the US neighbor up north. And the company sees this alliance as the basic template that they can use in other countries around the world…

By Arlene WeintraubSep 13, 2021 12:00am Fierce Pharma’s list of top antibody-drug conjugate contenders includes a mix of Big Pharma players and startups that are expecting major milestones in the coming months. (PDPics/Pixabay) After Pfizer launched Mylotarg, the first antibody-drug conjugate (ADC) in 2000, it seemed to be the long-awaited “magic bullet” in cancer; it was a drug…

Mehmet A N Şendur, Sercan Aksoy, Nurullah Zengin PMID: 22475602 DOI: 10.1056/NEJMc1201462 Comment on Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group.N Engl J Med. 2012 Jan…